Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adagrasib With or Without Pembrolizumab in Advanced KRAS G12C-Mutant NSCLC
jRCT2051250009Phase 3Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Classical Binding Small Molecules → Small Molecules
01
Overview
Phase 3, randomised trial of adagrasib and pembrolizumab in non-small cell lung cancer (NSCLC) (5 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Progression-free survival by BICR and Overall survival. Started Jul 2025; status: recruiting.
02
Drugs
adagrasibpembrolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2051250009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051250009.